Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
122 studies found for:    cholangiocarcinoma | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors
Condition: Cholangiocarcinoma
22 Recruiting Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy
Condition: Cholangiocarcinoma
Intervention: Drug: INCB054828
23 Recruiting Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma
Condition: Hilar Cholangiocarcinoma
Intervention: Other: liver transplantation combined with neoadjuvant therapy
24 Recruiting A Phase I/II Study Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
Condition: Cholangiocarcinoma
Interventions: Drug: Amphinex and Gemcitabine;   Drug: Gemcitabine and Cisplatin
25 Recruiting Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Radiation: Therasphere® in association with Gemcitabine and Cisplatin
26 Not yet recruiting Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Conditions: Non-Resectable Cholangiocarcinoma;   Recurrent Cholangiocarcinoma;   Stage III Extrahepatic Bile Duct Cancer;   Stage III Intrahepatic Cholangiocarcinoma;   Stage IIIA Hilar Cholangiocarcinoma;   Stage IIIB Hilar Cholangiocarcinoma;   Stage IVA Extrahepatic Bile Duct Cancer;   Stage IVA Hilar Cholangiocarcinoma;   Stage IVA Intrahepatic Cholangiocarcinoma;   Stage IVB Extrahepatic Bile Duct Cancer;   Stage IVB Hilar Cholangiocarcinoma;   Stage IVB Intrahepatic Cholangiocarcinoma;   Unresectable Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Ricolinostat
27 Recruiting Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: Dasatinib
28 Recruiting ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy
Condition: Cholangiocarcinoma
Intervention: Drug: Varlitinib
29 Recruiting Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Morphological Diagnosis of Hilar Cholangiocarcinoma (Excluded Type 1), Resectable With Expected R0 Margins on an intent-to Treat Basis.
Interventions: Procedure: CAPECITABINE-Radiotherapy -Liver Transplantation;   Procedure: RESECTION
30 Recruiting Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Conditions: Intrahepatic Cholangiocarcinoma;   Peripheral Cholangiocarcinoma;   Cholangiolar Carcinoma;   Cholangiocellular Carcinoma
Interventions: Drug: Floxuridine (FUDR);   Drug: dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Other: MRI;   Other: Research blood draws
31 Recruiting RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
Condition: Cholangiocarcinoma
Interventions: Drug: RRx-001;   Drug: Gemcitabine and cisplatin
32 Recruiting Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Conditions: Hepatocellular Carcinoma;   Intrahepatic Cholangiocarcinoma
Interventions: Device: Delcath Hepatic Delivery System;   Drug: Melphalan
33 Recruiting A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Condition: Metastatic Biliary Tract Carcinoma
Intervention: Drug: Regorafenib
34 Recruiting Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Liver Neoplasms
Interventions: Drug: Floxuridine;   Drug: Dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin
35 Recruiting Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Conditions: Biliary Carcinoma;   Gall Bladder Carcinoma;   Cholangiocarcinoma;   Gastrointestinal Tumor
Interventions: Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Copanlisib
36 Recruiting Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma
Condition: Cholangiocarcinoma
Interventions: Radiation: High Dose Radiation;   Drug: Systemic chemotherapy
37 Recruiting Regorafenib Versus Placebo to Treat Cholangiocarcinoma
Condition: Cholangiocarcinoma
Interventions: Drug: Regorafenib/active;   Drug: Regorafenib/placebo
38 Not yet recruiting Liver Transplantation for Early Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Procedure: Deceased donor Liver Transplantation
39 Recruiting A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: LDK378
40 Recruiting TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: TACE+Tegafur;   Procedure: TACE

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years